Santarus and Cosmo's colitis drug meets Phase III trial's key goal

09/29/2010 | Reuters

A Phase III study found that Santarus and Cosmo Pharmaceuticals' budesonide MMX worked better than a dummy pill at putting patients with mild or moderate active ulcerative colitis in remission after eight weeks. Both 9- and 6-milligram doses of the treatment were well tolerated, the drugmakers said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD